Evaluate for Venture Capital
Biotech and pharma investment intelligence for venture capital teams
Evaluate helps venture capital teams identify promising companies and assets, assess market potential, pressure-test investment assumptions and track the clinical, regulatory and commercial signals that could affect portfolio value.
Why venture capital teams use Evaluate
In pharma and biotech investing, the science is only part of the decision.
VC teams need to understand whether the market opportunity supports the investment case, how differentiated an asset really is, which competitors could affect the path to value, and what clinical, regulatory or commercial milestones may change the outlook.
Evaluate connects company, asset, forecast, pipeline and catalyst intelligence so your team can source opportunities, validate assumptions, monitor risks and support portfolio companies, using data aligned to the same market view trusted across pharma.
drugs across marketed and pipeline assets
biopharma companies across private and listed markets
event types covering clinical, regulatory, legal and commercial catalysts
Used by 98% of the top 50 pharma companies
Trusted intelligence across the pharma and biotech ecosystem
Built for investment teams, trusted accross pharma and biotech.
- Forecasts to 2032 for forward-looking market sizing and investment evaluation
- Historic sales data back to 1996 for long-term performance context
- Coverage across private and listed biopharma companies, marketed products and pipeline assets
Built for key venture capital workflows
Get in touch
Whether you are mapping a new therapy area, reviewing an early-stage opportunity, preparing for an investment committee or supporting a portfolio company through its next phase, we help you build a clearer view of the opportunity, risks and path to value.
Thesis-led sourcing and market mapping
Identify emerging companies, assets, modalities and therapy areas that align with your investment thesis.
Use Evaluate to map markets, track biopharma companies, review pipeline activity and identify where innovation, unmet need and commercial potential are converging.
Useful when you need to:
- Build a sourcing list around a therapy area, modality or market trend
- Identify companies active in high-growth or under-served markets
- Prioritize opportunities for deeper review
Commercial due diligence
Test whether the commercial opportunity supports the investment case.
Use Evaluate to assess forecast potential, indication strategy, competitive intensity, clinical stage, regulatory milestones and market dynamics behind a potential investment.
Useful when you need to:
- Validate market size and growth assumptions
- Assess the commercial potential of an asset or platform
- Compare a company against relevant competitors
Investment committee support
Build stronger investment recommendations with clearer evidence.
Use Evaluate to support IC discussions with data on market opportunity, competitive dynamics, forecast potential, clinical milestones, peer companies and comparable assets.
Useful when you need to:
- Strengthen investment memos
- Pressure-test commercial assumptions
- Benchmark companies against relevant peer
Portfolio value creation
Support portfolio companies as they move through development, fundraising, partnering and commercial planning.
Use Evaluate to monitor market shifts, assess competitor activity, identify relevant catalysts and build evidence for investor, partner or acquirer conversations.
Useful when you need to:
Support portfolio planning and market prioritisation
Prepare companies for future funding rounds
Identify strategic partnership or licensing opportunities
Catalyst and risk monitoring
Track the events that could change an investment thesis or portfolio valuation.
Use Evaluate to monitor trial readouts, regulatory decisions, approvals, patent events, competitor updates, M&A activity and other market-moving developments.
Useful when you need to:
Monitor portfolio company risks
Track competitor milestones
Identify follow-on investment moments
Partnering, exit and licensing analysis
Assess the routes that could create value, from licensing and co-development to acquisition or IPO.
Use Evaluate to understand comparable assets, relevant pharma partners, market potential and competitive dynamics, making it easier to shape realistic partnering and exit strategies.
Useful when you need to:
Identify potential pharma partners or acquirers
Assess licensing potential
Support IPO or M&A readiness
The data and tools behind the workflows
Evaluate gives VC teams a connected view of the companies, assets, forecasts, pipelines, events and market commentary behind pharma and biotech investment decisions.
Consensus forecasts and sales data
Size markets, assess future commercial potential and benchmark assets across therapy areas, indications and companies.
Company and asset coverage
Track private and listed biopharma companies, marketed products and pipeline assets.
Pipeline intelligence
Review development stage, indication focus, clinical progress and competitor activity.
NPV Analyzer
Model future sales, risk assumptions, competitive threats and development scenarios.
Calendar of Events
Monitor clinical, regulatory, legal and commercial catalysts that could affect company value or investment timing.
Peer Group Analyzer
Compare companies against relevant peers to support market mapping, diligence, benchmarking and IC discussions.
News & Insights
Keep up to date with the market signals shaping pharma and biotech investment decisions through expert analysis, exclusive interviews and market commentary
Build stronger pharma and biotech investment strategies with Evaluate
See how Evaluate helps venture capital teams source opportunities, assess market potential, monitor risks and support portfolio companies with trusted biopharma intelligence.
Frequently Asked Questions
How can Evaluate support early-stage biotech investing?
Evaluate helps VC teams assess the commercial case behind emerging biotech opportunities, including market potential, pipeline activity, competitive dynamics, catalysts and forecast assumptions.
Can Evaluate help with private company research?
Yes. Evaluate covers private and listed biopharma companies, helping teams build market maps, identify emerging players and understand where innovation is concentrated.
How does Evaluate support investment committee materials?
Evaluate provides evidence around market size, forecast potential, competitive positioning, development timelines, catalyst exposure and peer comparisons, helping teams pressure-test assumptions and build stronger IC materials.
Can Evaluate help portfolio companies?
Yes. VC teams can use Evaluate to support portfolio companies with market prioritisation, competitor tracking, fundraising preparation, partnering strategy and exit planning.
Can Evaluate help identify potential pharma partners or acquirers?
Yes. Evaluate helps teams assess comparable assets, competitor activity, market opportunity and relevant company activity across the pharma and biotech landscape, supporting licensing, partnering and exit planning.
